Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | CCNC | P24863 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TARS1 | P26639 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29314761 | 0.95 | TLR7 (0.42) | TLR7TLR8MTNR1BMTNR1ANLRP3 | |
| SCHEMBL26785870 | 0.93 | NLRP3 (0.34) | TLR7TLR8MTNR1BMTNR1ANLRP3 | |
| SCHEMBL23037710 | 0.92 | TLR7 (0.40) | TLR7TLR8NLRP3NAMPT | |
| SCHEMBL29057286 | 0.91 | TLR7 (0.40) | TLR7TLR8MTNR1BMTNR1ANLRP3 | |
| SCHEMBL29320204 | 0.90 | TLR7 (0.38) | TLR7TLR8NLRP3NAMPTCYP3A4 | |
| SCHEMBL23037589 | 0.90 | TLR8 (0.38) | TLR7TLR8NLRP3NAMPT | |
| SCHEMBL30539846 | 0.90 | TLR8 (0.38) | TLR7TLR8NLRP3NAMPT | |
| SCHEMBL29057282 | 0.90 | TLR7 (0.42) | TLR7TLR8MTNR1BMTNR1ANAMPT | |
| SCHEMBL29320220 | 0.90 | TLR8 (0.37) | TLR7TLR8NAMPT | |
| SCHEMBL27194825 | 0.89 | NLRP3 (0.37) | TLR7TLR8NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | TLR7 236/4885TLR8 210/4885MTNR1B 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.